This study demonstrates that obese T2DM patients with MAFLD exhibit significant glucolipid metabolic disorders, impaired islet function, hepatic dysfunction, and elevated inflammatory markers, including BMI, FPG, FINS, HOMA-IR, HbA1c, TC, TG, LDL-C, ALT, AST, and IL-6 levels, all significantly higher than healthy controls
This substance is not for human or veterinary use and is not an FDA-approved drug
These issues can negatively impact patient satisfaction, treatment adherence, and healthcare provider confidence in prescribing these drugs
A 34-year-old female patient with a history of mild psoriasis for which she was not receiving treatment was started on liraglutide for insulin resistance